Arrowhead Research to fire CSO David Lewis
Dr. Lewis, Chief Scientific Officer, has served in this role since September 2013. From October 2011 until September 2013, he served as the Companys Vice President, Biology.
Dr. Lewis has served as Site Head for the Companys Research and Development facility in Madison, Wisconsin since 2011 and prior to that as Site Head for the facility under Roche ownership from 2008 until 2011.
Dr. Lewis is a pioneer in the use of RNAi and was the first to show that siRNAs could be used to inhibit gene expression in multiple tissues of adult mammals.
Dr. Lewis received his B.S. degree in Biochemistry and Molecular Biology from the University of Wisconsin-Madison, and his Ph.D. degree in Biochemistry from Michigan State University.
Dr. Lewis went on to the Howard Hughes Medical Institute at the University of Wisconsin-Madison to perform post-doctoral studies.
He has authored 25 scientific papers and book chapters, has 19 patents, and has been awarded government-sponsored research grants totaling more than $5 million. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST